XIX FIGO WORLD CONGRESS OF GYNECOLOGY AND OBSTETRICS INDUSTRY-SPONSORED SYMPOSIA Monday, 5 October 2009 13h00-14h15 Ballroom East (CTICC) Contraception and Beyond: Evidence-based Indications for LNG-IUS 1. Wider Use of Intrauterine Contraception - David Grimes
2. The LNG-IUS in Heavy Menstrual Bleeding: First-line Treatment Based on Comprehensive Clinical Data - Anita Nelson
3. Safety and Efficacy of Consecutive Use of the LNG-IUS - Confirmed by a New Study -Kristina Gemzell-Danielsson
Symposium sponsored by Bayer Schering Pharma Ballroom West (CTICC) The Role of GARDASIL™ in Reducing the Global Burden of Cervical Cancer and Other HPV-Related Diseases 1. Opening Remarks – Lynette Denny, South Africa
2. Global HPV Epidemiology and Burden of Disease - Lynette Denny, South Africa3. Gardasil Efficacy and Recent Clinical Data - Suzanne M. Garland, Australia
4. MSD’s Commitment: Access to Gardasil in the Developing World - Carlos Sattler, USA
Symposium sponsored by MSD Tuesday, 6 October 2009 13h00-14h15 Ballroom East (CTICC) Innovation in Contraception 1. Ethinylestradiol 20mcg/Drospirenone 3mg Administered in a 24/4 Regimen: A New OC Goes Beyond Contraception - Joachim Marr and Lorraine Dennerstein
2. A New OC Concept with Additional Benefit - Wolfgang Holzgreve and Klaus Pietrzik
Symposium sponsored by Bayer Schering Pharma Ballroom West (CTICC) Overactive Bladder: TIME to take notice Chairman’s Introduction
1. The Burden and Implications of OAB – Linda Cardozo, UK2. Initial Diagnosis and Assessment of Women with LUTS - Mickey Karram, USA3. Making Sure We Understand Our Patient’s Needs – Peter de Jong, South Africa
4. Ensuring Successful Management with Pharmacotherapy - Willy Davilla, USA
Symposium sponsored by Astellas Pharma Wednesday, 7 October 2009 13h00-14h15 Ballroom East (CTICC) Evolution of a Revolution: Introducing a New Class of Oral Contraceptive
1. Introducing E2V/DNG - Ian Fraser2. E2V/DNG: Contraceptive Efficacy and Safety Data - Jeffrey T. Jensen
3. First Experience with the Estradiol Based Combined Oral Contraceptive E2V/DNG - Diana Mansour
Symposium sponsored by Bayer Schering Pharma Ballroom West (CTICC) Effective Solutions for Enhanced Obstetric Management 1. New Ultrasound Technologies in Assisted Reproductive Medicine SonoAVC - Nick Raine Fenning, Nottingham, UK
2. Enhancing the Monitoring Experience from Antepartum through to Postpartum - Philippe Barjot, Caen, France
3. Improving Obstetric Workflow, Archiving and Reporting - Philippe Barjot, Caen, France
Symposium sponsored by GE Healthcare Thursday, 8 October 2009 13h00-14h15 Ballroom East (CTICC) Improving Women's Healthcare - a Contemporary View Chair: Jennifer Blake 1. Progestins - An Important Versatile Class – Peter Rogers
2. Specialised Progestins I - Dienogest in Endometriosis - Alfred Mueck3. Specialised Progestins II – Drospirenone in Menopause - Tommaso Simoncini
Symposium sponsored by Bayer Schering Pharma Ballroom West (CTICC) Cervarix®: Focusing on the Global Needs of Cervical Cancer Vaccination 1. Welcome and Introduction – Anne Szarewski, UK and Hugues Bogaerts, Belgium
2. The Relevance of the HPV Type Distribution in Cervical Cancer – F. Xavier Bosch, Spain3. Understanding the Immunological Potential of HPV Vaccines – Peter L. Stern, UK4. Cervarix®: The Benefits to Girls and Women: From Clinical Trials to Clinical Practice – Anne
Symposium sponsored by GlaxoSmithKline
SCA Protocol for the Prevention of Tick-Borne Illness Because SCA has experienced increased incidence of embedded ticks and Lyme disease, when working in areas with known high populations of ticks and based on a job hazard assessment, the following protocol for the prevention of tick borne illnesses has been developed. 1. Cease or do not engage in service in areas with an unmanageabl
Tamiflu users say side effects are common One-third of patients report nausea; some children experience mental conditions Nausea, headaches and vomiting are the most common side effects of the popular flu drug Tamiflu—and they occur more severely in young children than adults, consumers tell Askapatient.com. Tamiflu ( oseltamivir phosphate) is approved for children over 1, but Askapat